Prophylactic Interventions to Prevent Severe Skin Toxicities in Patients With Non–Small Cell Lung Cancer Treated With Nivolumab + Ipilimumab With or Without Chemotherapy
Prophylactic interventions significantly reduced the severity of skin toxicities and enhanced treatment continuity in patients with NSCLC receiving nivolumab and ipilimumab-based therapy. These findings underscore the importance of proactive, multidisciplinary management strategies to optimize therapeutic outcomes.
Authors
- M. Kagawa
- Hirofumi Chiba (ORCID: https://orcid.org/0000-0002-7033-3084)
- Toshiyuki Sumi (ORCID: https://orcid.org/0000-0002-2540-5878)
- Keigo Matsuura
- Shunsuke Tsuji
- K. Kanamaru
- Takumi Ikeda (ORCID: https://orcid.org/0000-0003-0527-3078)
- Yuichi Yamada (ORCID: https://orcid.org/0000-0002-9080-4496)
- Taiki Ishigooka
Institutions
- Sapporo Medical University (JP)
- Hakodate National Hospital (JP)
Publication Details
- Journal
- JCO Oncology Practice
- Published
- 2025-06-30
- DOI
- https://doi.org/10.1200/op-25-00100
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05